Ortho Clinical Diagnostics Holdings Plc's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the first quarter 2022 to a ratio of 8.46, above the company average. This is a clear sign of healthy business climate in the In Vitro & In Vivo Diagnostic Substances industry and improving liquidity at their respective customers, during the first quarter 2022. Average receivable collection period, for the Ortho Clinical Diagnostics Holdings Plc in Apr 03 2022 quarter, has decreased to 43 days, compared to 47 days, in the Jan 02 2022 quarter.

If we take a look into Healthcare sector 202 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 1854, from overall ranking in the fourth quarter 2022 at 4273.

What is Receivable Turnover Ratio?
What is Ortho Clinical Diagnostics Holdings Plc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

OCDX Receivables Turnover Ratio	(Apr 03 2022) I. Quarter	(Jan 02 2022) IV. Quarter	(Oct 03 2021) III. Quarter	(Jul 04 2021) II. Quarter	(Apr 04 2021) I. Quarter
Y / Y Receivable Change	-25.64 %	-19.3 %	-	-	-
Y / Y Revenue Change	-1.32 %	0.83 %	15.83 %	26.12 %	24.25 %
Receivable Turnover Ratio (TTM)	8.46	7.82	7.37	9.05	11.61
OCDX's Total Ranking	# 1854	# 4273	# 0	# 3974	# 0
Accounts Receivable average collection period days	43	47	50	40	31
Seq. Receivable Change	-6.3 %	8.16 %	5.04 %	-30.15 %	1.69 %
Seq. Revenue Change	-4.01 %	-0.29 %	6.09 %	-2.82 %	-1.92 %

Receivable Turnover Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 6
Healthcare Sector	# 203
Overall Market	# 1854

Receivable Turnover Ratio Statistics
High	Average	Low
0.61	0.61	0.61
(Apr 03 2022)		(Jan 02 2022)

OCDX Company Profile • Back to OCDX Efficiency Comparisons • Compare OCDX Receivables Turnover Ratio to its Competitors

Financial Statements
Ortho Clinical Diagnostics Holdings Plc's Accounts Receivable	$ 241 Millions	Visit OCDX's Balance sheet
Ortho Clinical Diagnostics Holdings Plc's Sales TTM	$ 2,036 Millions	Visit OCDX's Income Statement
Sources of OCDX's Revenues		Visit OCDX's Sales by Geography

Other Accounts Receivable Turnover Ratios
In Vitro & In Vivo Diagnostic Substances Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
OCDX's Receivable Turnover Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
OCDX's Growth Rates	OCDX's Roa	OCDX's Inventory Turnover Ratio	OCDX's Dividend Comparisons
OCDX's Profitability Ratios	OCDX's Roi	OCDX's Asset Turnover Ratio	OCDX's Dividend Growth
OCDX's Valuation Ratios	OCDX's Roe	OCDX's Financial Strength Ratios	OCDX's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Apr 03 2022, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Apr 03 2022	Receivable at quarter ending Apr 03 2022
Qhslab Inc	22.25	$ 1.465 Millions	$ 0.066 Millions
Scorpius Holdings inc	21.03	$ 1.787 Millions	$ 0.085 Millions
Catalyst Pharmaceuticals Inc	20.44	$ 153.717 Millions	$ 7.522 Millions
Theralink Technologies Inc	20.18	$ 0.504 Millions	$ 0.025 Millions
Vtv Therapeutics Inc	19.26	$ 5.018 Millions	$ 0.261 Millions
Innovage Holding Corp	19.20	$ 697.395 Millions	$ 36.326 Millions
Cadre Holdings inc	18.37	$ 421.158 Millions	$ 22.922 Millions
Talphera Inc	18.30	$ 2.749 Millions	$ 0.150 Millions
Intellia Therapeutics Inc	18.21	$ 37.860 Millions	$ 2.079 Millions
Nutriband Inc	17.74	$ 1.467 Millions	$ 0.083 Millions
Immunogen inc	17.73	$ 92.228 Millions	$ 5.201 Millions
Ethema Health Corporation	17.37	$ 2.875 Millions	$ 0.166 Millions
Chemed Corporation	17.36	$ 2,152.820 Millions	$ 124.015 Millions
Denali Therapeutics Inc	17.26	$ 82.879 Millions	$ 4.801 Millions
23andme Holding Co	17.25	$ 271.893 Millions	$ 15.763 Millions
Janux Therapeutics Inc	16.95	$ 1.589 Millions	$ 0.094 Millions
Arbutus Biopharma Corp	16.58	$ 21.456 Millions	$ 1.294 Millions
Jrsis Health Care Corp	16.46	$ 52.684 Millions	$ 3.200 Millions
Electrocore Inc	16.38	$ 6.146 Millions	$ 0.375 Millions
Histogen Inc	16.35	$ 4.356 Millions	$ 0.266 Millions
Travere Therapeutics Inc	16.31	$ 228.570 Millions	$ 14.016 Millions
Neurometrix Inc	16.07	$ 8.400 Millions	$ 0.523 Millions
Chinook Therapeutics Inc	16.01	$ 53.971 Millions	$ 3.371 Millions
Bionexus Gene Lab Corp	15.96	$ 12.942 Millions	$ 0.811 Millions
Reflect Scientific Inc	15.74	$ 3.006 Millions	$ 0.191 Millions
Lftd Partners Inc	15.67	$ 46.393 Millions	$ 2.960 Millions
Apellis Pharmaceuticals Inc	15.66	$ 80.944 Millions	$ 5.169 Millions
Sonendo Inc	15.36	$ 34.803 Millions	$ 2.266 Millions
Sangamo Therapeutics Inc	15.05	$ 112.652 Millions	$ 7.483 Millions
Celldex Therapeutics inc	14.95	$ 4.140 Millions	$ 0.277 Millions

Date modified: 2026-08-29T17:43:13+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.